Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Research article

Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice

Authors: Yan-Hong Liu, Hua-Yan Qin, Yuan-Yuan Zhong, Shuang Li, Hua-Jing Wang, Hong Wang, Li-Ling Chen, Xiang Tang, Ya-Lin Li, Zhong-Yi Qian, Huai-Yu Li, Lei Zhang, Tong Chen

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Our previous studies demonstrated that the administration of crude Polysaccharide from Panax notoginseng (CPPN) can effectively prolong the lifespan of tumor-bearing mice via boosting the host immune system as well as weak cytotoxicity against hepatocellular carcinoma (HCC). In the present study, Neutral Polysaccharide (NPPN) were further purified from crude polysaccharide isolated from panax notoginseng. The effects of NPPN on the immune function and hematopoietic function of mice with low immunity and myelosuppression induced by cyclophosphamide (CTX) were investigated. The effect of NPPN combined with CTX on the tumor inhibition rate of the H22 tumor-bearing mice and the impact of NPPN on the proliferation of H22 liver cancer cells in vitro were investigated.

Methods

CPPN was obtained by water extraction and alcohol precipitation method, and further purified by DEAE Sepharose Fast Flow ion exchange resin column. NPPN was added to the immunosuppressed with myelosuppression mice induced by CTX. Thymus index, spleen index, lymphocyte proliferation stimulation index by adding of concanavalin A, determination of serum hemolysin, NK cell activity assay, mice carbon clearance experiment, blood count tests were detected. The tumor inhibition rate of the H22 tumor-bearing mice treated with NPPN combined with CTX was recorded.

Results

NPPN and 4 kinds of acid polysaccharide from Panax notoginseng (APPN) were successfully isolated from the CPPN by DEAE Sepharose Fast Flow ion exchange resin column. NPPN inhibited the growth of H22 cells and significantly increase the tumor inhibition rate of the H22 tumor-bearing mice combined with CTX. The elevation of the cellular and humoral immunity levels as well as a variety of blood count tests indicators of immunosuppressive with myelosuppression mice may contribute to the antitumor activity of NPPN.

Conclusion

NPPN has a potential antitumor activity for the treatment of liver cancer combined with cyclophosphamide.
Literature
1.
2.
Shi JS, Jin X, Wang MQ, et al. Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. C M J. 2012;125(2):197–202.
3.
Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536–9.PubMedCrossRef
4.
Saba NF, Salama JK, Beitler JJ, et al. ACR appropriateness criteria® for nasopharyngeal carcinoma. Head Neck. 2016;38(7):979–86.PubMedCrossRef
5.
Wang MM, Tian HM, Li G, et al. Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Oncotarget. 2016;7(30):48375–90.PubMedPubMedCentralCrossRef
6.
Chen XM, Nie WJ, Fan SR, et al. A polysaccharide from Sargassum fusiforme protects against immunosuppression in cyclophosphamide-treated mice. Carbohydr Polym. 2012;90(2):1114–9.PubMedCrossRef
7.
Baig H, Somlo B, Eisen M, et al. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. J Oncol Pharm Pract. 2019;25(7):1576–85.PubMedCrossRef
8.
Gao H, Wang FZ, Lien EJ, et al. Immunostimulating polysaccharides from Panax notoginseng. Pharm Res. 1996;13(8):1196–200.PubMedCrossRef
9.
Lien EJ. Fungal metabolites and Chinese herbal medicine as immunostimulants. Prog Drug Res. 1990;34:395–420.PubMed
10.
Li XY. Immunomodulating Chinese herbal medicines. Mem Inst Oswaldo Cruz. 1991;86(Suppl 2):159–64.PubMedCrossRef
11.
Ohtani K, Mizutani K, Hatono S, et al. Sanchinan-A, a reticuloendothelial system activating arabinogalactan from sanchi-ginseng (roots of Panax notoginseng). Planta Med. 1987;53(2):166–9.PubMedCrossRef
12.
Zhao SY, Chen T, Zhang YW, et al. Extraction and determination of polysaccharide in Panax notoginseng. West China J Pharm Sci. 2011;26(05):481–3.
13.
Li HY, Gu LL, Zhong YY, et al. Administration of polysaccharide from Panax notoginseng prolonged the survival of H22 tumor-bearing mice. Oncotargets Ther. 2016;9:3433–41.
14.
Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer. 2008;100(10):698–711.CrossRef
15.
Qu JY, Tian M, He JH, et al. Impact of polysaccharides of Hedyotis diffusa on immune function in immunosupperession mice. Chin Med Mat. 2015;38(09):1942–5.
16.
Ye YX, Lin L, Zhao JX, et al. Effect of polysaccharides of Eucommin ulmides leaves on immune function in immunosuppression mice. Chin Med Mat. 2015;38(07):1496–8.
17.
Li ZH, Zhang N, Dong WR, et al. Effect of polysaccharides of Radix scrophulariae on immune function in mice under normal physiological and hypoimmunical state. J China Pharm. 2017;28(10):1316–9.
18.
Li HY, Zhong YY, Li S, et al. Isolation and purification of Panax notoginseng polysaccharide and its effect on proliferation of human periodontal ligament stem cells and mice osteoblasts in vitro West China. J Pharm Sci. 2019;34(05):433–9.
19.
Yoshikawa M, Murakami T, Ueno T, et al. Bioactive saponins and glycosides. VIII. (1) Notoginseng (1): new dammarane-type triterpene oligoglycosides, notoginsenosides-A, −B, −C, and -D, from the dried root of Panax notoginseng (BURK.) F. H. CHEN. C Chem Pharm Bull. 1997;45(6):1039–45.CrossRef
20.
Li HZ. A novel hexa-nordammarane glycoside from the roots of Panax notoginseng. Chin Chem Lett. 2001;12:59–62.
21.
Ma WG, Mizutani M, Malterud KE, et al. Saponins from the roots of Panax notoginseng. Phytochemistry. 1999;52(6):1133–9.CrossRef
22.
Sun HX, Yang ZG, Ye YP. Structure and biological activity of protopanaxatriol-type saponins from the roots of Panax notoginseng. Int Immunopharmacol. 2006;6(1):14–25.PubMedCrossRef
23.
Yoshikawa M, Morikawa T, Yashiro K, et al. Bioactive saponins and glycosides. XIX. (1) Notoginseng (3): immunological adjuvant activity of notoginsenosides and related saponins: structures of notoginsenosides-L, −M, and -N from the roots of Panax notoginseng (BURK.) F. H. CHEN. Chem Pharm Bull. 2001;49(11):1452–6.CrossRef
24.
Wan JB, Lai CM, Li SP, et al. Simultaneous determination of nine saponins from Panax notoginseng using HPLC and pressurized liquid extraction. J Pharm Biomed Anal. 2006;41(1):274–9.PubMedCrossRef
25.
Liu JW, Tian SJ, de Barry J, et al. Panaxadiol glycosides that induce neuronal differentiation in neurosphere stem cells. J Nat Prod. 2007;70(8):1329–34.PubMedCrossRef
Metadata
Title
Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice
Authors
Yan-Hong Liu
Hua-Yan Qin
Yuan-Yuan Zhong
Shuang Li
Hua-Jing Wang
Hong Wang
Li-Ling Chen
Xiang Tang
Ya-Lin Li
Zhong-Yi Qian
Huai-Yu Li
Lei Zhang
Tong Chen
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07742-z

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research article

Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China

Research article

A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019

Research article

Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation

Research

Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ

Research article

MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?

Research article

Prognostic role of preoperative D-dimer, fibrinogen and platelet levels in patients with oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits